Breaking New Ground
The Sharon Eccles Steele Center for Translational Medicine (SCTM) was founded in 2009 to effectively turn scientific discoveries into clinical diagnostic tools and therapies for patients suffering from blinding diseases.
The SCTM is primarily focused on developing treatments for age-related macular degeneration (AMD), a leading cause of vision impairment among adults age 55 and over. AMD affects more than 20 million individuals in the United States, and its prevalence is projected to double by 2050. AMD causes a gradual loss of vision that results in significantly reduced quality of life and often depression. Progression to the late stage of AMD often leads to irreversible vision loss.
With the support of committed donors, SCTM Executive Director Gregory S. Hageman, PhD, and his team have turned a series of groundbreaking discoveries into scientifically sound strategies to prevent the onset of all forms of AMD or to slow their progression.